GENEDX, LLC
Clinical genetic testing company
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 3 of its records are shown together here.
Reported lobbying by year
Filings
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Report 3rd Quarter 2026
|
MICHAEL BEST STRATEGIES LLC | $30,000 reported |
|
3rd Quarter - Report 3rd Quarter 2026
|
RED+BLUE STRATEGIES | $80,000 reported |
|
Registration 3rd Quarter 2026
|
MICHAEL BEST STRATEGIES LLC | — reported |
|
2nd Quarter - Report 2nd Quarter 2026
|
RED+BLUE STRATEGIES | $80,000 reported |
|
1st Quarter - Report 1st Quarter 2026
|
RED+BLUE STRATEGIES | $80,000 reported |
|
4th Quarter - Report 4th Quarter 2025
|
RED+BLUE STRATEGIES | $80,000 reported |
|
3rd Quarter - Report 3rd Quarter 2025
|
RED+BLUE STRATEGIES | $80,000 reported |
|
2nd Quarter - Amendment 2nd Quarter 2025
|
RED+BLUE STRATEGIES | $80,000 reported |
|
2nd Quarter - Reportreplaced 2nd Quarter 2025
|
RED+BLUE STRATEGIES | $30,000 reported |
|
Registration 2nd Quarter 2025
|
RED+BLUE STRATEGIES | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| RED+BLUE STRATEGIES | 6 | $480,000 |
| IPOLICY SOLUTIONS | 3 | $52,500 |
| MICHAEL BEST STRATEGIES LLC | 1 | $30,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 9 |
| Medicare/Medicaid | MMM | 8 |
| Defense | DEF | 3 |
| Medical/Disease Research/Clinical Labs | MED | 3 |
| Insurance | INS | 2 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.